- Home
- BATL vs ELEV Comparison
BATL vs ELEV Comparison
Compare BATL & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- ELEV
- Stock Information
- Founded
- BATL 1987
- ELEV 2019
- Country
- BATL United States
- ELEV United States
- Employees
- BATL N/A
- ELEV N/A
- Industry
- BATL Oil & Gas Production
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- ELEV Health Care
- Exchange
- BATL Nasdaq
- ELEV Nasdaq
- Market Cap
- BATL 20.6M
- ELEV 22.6M
- IPO Year
- BATL N/A
- ELEV 2021
- Fundamental
- Price
- BATL $1.35
- ELEV $0.37
- Analyst Decision
- BATL
- ELEV Hold
- Analyst Count
- BATL 0
- ELEV 6
- Target Price
- BATL N/A
- ELEV $1.77
- AVG Volume (30 Days)
- BATL 113.7K
- ELEV 1.2M
- Earning Date
- BATL 08-13-2025
- ELEV 08-05-2025
- Dividend Yield
- BATL N/A
- ELEV N/A
- EPS Growth
- BATL N/A
- ELEV N/A
- EPS
- BATL N/A
- ELEV N/A
- Revenue
- BATL $191,498,000.00
- ELEV N/A
- Revenue This Year
- BATL N/A
- ELEV N/A
- Revenue Next Year
- BATL N/A
- ELEV N/A
- P/E Ratio
- BATL N/A
- ELEV N/A
- Revenue Growth
- BATL N/A
- ELEV N/A
- 52 Week Low
- BATL $1.05
- ELEV $0.22
- 52 Week High
- BATL $6.89
- ELEV $3.09
- Technical
- Relative Strength Index (RSI)
- BATL 45.53
- ELEV 45.79
- Support Level
- BATL $1.31
- ELEV $0.35
- Resistance Level
- BATL $1.40
- ELEV $0.38
- Average True Range (ATR)
- BATL 0.09
- ELEV 0.01
- MACD
- BATL 0.00
- ELEV -0.00
- Stochastic Oscillator
- BATL 63.64
- ELEV 34.34
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.